Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Medulloblastoma, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Group 3 MYC-amplified and SHH TP53-mutant tumours: survival under 50%.
Relapse after craniospinal irradiation is rarely curable; it is where new approaches are most needed.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Neurocognitive, endocrine and hearing sequelae in survivors.
Infants: curing Group 3 without radiation.
Access to proton therapy and methylation profiling globally.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Involved-field boost non-inferior (5-year EFS 82.
Carboplatin radiosensitisation improved event-free and overall survival in group 3 high-risk medulloblastoma; isotretinoin maintenance was stopped for futility.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
15-year all-cause mortality among five-year survivors fell from 12.